摘要
目的探讨安宫牛黄丸联合依达拉奉右莰醇治疗重症脑梗死的临床效果。方法选取2022年7月-2023年12月天台县人民医院收治的重症脑梗死患者100例,采用随机数字表法分为对照组与观察组,每组50例。对照组给予依达拉奉右莰醇治疗,观察组采用安宫牛黄丸联合依达拉奉右莰醇治疗。比较两组美国国立卫生研究院卒中量表(NIHSS)评分、血清超敏C反应蛋白(hs-CRP)水平、改良Rankin量表(mRS)评分和不良反应发生情况。结果治疗后14 d,观察组的NIHSS评分、血清hs-CRP水平低于对照组;治疗后6个月,观察组的mRS评分低于对照组;观察组治疗总有效率高于对照组(P<0.05);两组均未见明显不良反应。结论安宫牛黄丸联合依达拉奉右莰醇治疗重症脑梗死效果显著,可明显改善神经功能、血清炎症指标和生活能力,且安全性高。
Objective To explore the clinical effect of Angong Niuhuang Pills combined with edaravone dexborneol in the treatment of severe cerebral infarction.Methods A total of 100 patients diagnosed with severe cerebral infarction,who were admitted to Tiantai People's Hospital between July 2022 and December 2023,were recruited for this study.These patients were then allocated into a control group and an observation group in accordance with the random number table method,with 50 patients in each group.The control group was given edaravone dexborneol treatment,and the observation group was treated with Angong Niuhuang Pills combined with edaravone dexprenol.The scores of the National Institute of Health Stroke Scale(NIHSS),the levels of serum hypersensitive C-reactive protein(hs-CRP),the scores of the modified Rankin Scale(mRS),as well as the incidence of adverse reactions were contrasted between the two groups.Results 14 days after treatment,the observation group exhibited significantly lower NIHSS scores and reduced serum hs-CRP levels;at 6 months after treatment,the observation group demonstrated a lower mRS score;additionally,the observation group achieved a higher treatment efficacy rate(P<0.05).No obvious adverse reactions were observed in both groups.Conclusions The treatment of severe cerebral infarction with Angong Niuhuang Pills combined with edaravone dexborneol has a significant effect.It can significantly improve neurological function,serum inflammatory indicators,and living ability,and has high safety.
作者
赖针珍
王发明
LAI Zhenzhen;WANG Faming(Department of Neurology,Tiantai People's Hospital,Tiantai Branch of Zhejiang Provincial People's Hospital,Taizhou,Zhejiang 317200,China)
出处
《医药前沿》
2025年第6期81-84,共4页
Journal of Frontiers of Medicine
基金
浙江省医学会临床科研基金(2022ZYC-A104)。
关键词
安宫牛黄丸
依达拉奉右莰醇
重症脑梗死
神经功能
超敏C反应蛋白
生活能力
Angong Niuhuang Pills
Edaravone dexborneol
Severe cerebral infarction
Neurological function
Hypersensitive C-reactive protein
Living ability
